Clinical trials
Immunization; Infection clinical trials
Below are recruiting immunization; infection clinical trials, each written for real people, not researchers. We’re tracking 91 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06931002Recruiting
Cold virus study in bronchiectasis and healthy volunteers
This study tests whether giving a common cold virus (rhinovirus) to people with bronchiectasis and healthy volunteers can trigger a lung flare-up. It aims to understand how the immune system responds and what causes exacerbations, which could lead to better treatments.
LondonAges 18–65 - NCT07202065RecruitingPhase 2/Phase 3
Preventing infections with antibiotics or immunoglobulin in blood disorders
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
Adelaide, South AustraliaAges 18 years+ - NCT05371353Recruiting
Study of how long HPV vaccine immunity lasts
This study checks how well the HPV (cancer-preventing) vaccine protection stays in your body over time. It may help confirm the vaccine’s “long-lasting” immune response and guide future vaccination confidence.
Yangchun, GuangdongAges 9–45 - NCT04970836Recruiting
Hepatitis B revaccination for young adults in Taiwan
This study looks at how well your immune system responds after getting 1–2 extra doses of the hepatitis B vaccine. It may help doctors understand who needs revaccination and how to strengthen protection.
TaipeiAges 20–36 - NCT07379580RecruitingPhase 2
Test of an mRNA vaccine for mpox in Africa
This trial tests a new mRNA vaccine to prevent mpox. It looks at how safe and effective the vaccine is in adults who have or haven't been exposed to mpox or similar viruses before.
KinshasaAges 18–64 - NCT07232706RecruitingPhase 3
RSV prevention in infants with nirsevimab and maternal vaccine
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
La Roche-sur-YonAges 18 years+ - NCT07202078RecruitingPhase 2/Phase 3
Starting immunoglobulin for infection prevention in hematology
This trial tests whether giving immunoglobulin to adults with low antibody levels can prevent infections. It aims to compare immunoglobulin with antibiotic therapy or no added treatment for people with blood conditions.
Adelaide, South AustraliaAges 18 years+ - NCT07833852Enrolling by invitation
Long-term protection study for bivalent HPV vaccine
This study follows up with people who received the bivalent HPV vaccine to see how long their protection lasts and whether any breakthrough infections occur. It involves extra blood tests or follow-up visits over several years.
Mianyang, SichuanAges 12–34 - NCT06168032Recruiting
COVID-19 vaccine for lung cancer patients
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
BeijingAges 18 years+ - NCT01397669Recruiting
Study immune differences in HIV and HIV-negative adults
This research compares the immune system in the gut lining, spinal fluid, lymph nodes, and blood between people living with HIV and people not living with HIV. Results may help scientists understand how immunity works and how it differs with HIV.
Bangkok, BangkokAges 18–50 - NCT06718530Recruiting
Finding early markers for liver cancer in people with chronic liver disease
This study looks for substances in your blood and immune system that could help doctors find liver cancer earlier. It is for people with liver cancer caused by chronic liver problems like hepatitis C, cirrhosis, or scarring.
Aviano, PordenoneAges 18 years+ - NCT07698600RecruitingPhase 1
Safety test of a new HIV vaccine in adults with or without HIV
This study tests a new RNA-based vaccine called BNT168 to see if it is safe and how the body responds to it. It is for healthy adults with or without HIV, and those with HIV will pause their regular treatment for a while during the study.
Houston, TexasAges 18–50 - NCT07286370RecruitingPhase 2
Vaccine study for typhoid and salmonella in infants
This study tests a new vaccine that could protect infants against typhoid fever and a serious type of salmonella. If your baby is healthy and within the age range, they may be eligible to participate.
BanjulAges 1 month–6 months - NCT07202091RecruitingPhase 2/Phase 3
Stopping or extending immunoglobulin therapy to prevent infections
This trial tests whether it is safe to stop or extend immunoglobulin (Ig) therapy for people with low antibody levels, or if switching to preventive antibiotics works just as well to prevent infections.
Adelaide, South AustraliaAges 18 years+ - NCT07189936RecruitingPhase 2
Testing 2-HOBA for Immune Issues in Long COVID with POTS
This trial tests if a medication called 2-HOBA can help with ongoing immune system issues in people with Long COVID who also have POTS. It aims to reduce fatigue and other symptoms by calming overactive immune responses.
Nashville, TennesseeAges 18 years+ - NCT05584397Enrolling by invitation
Compare immune activity and HIV hidden reservoir on two treatments
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Seattle, WashingtonAges 18–65 - NCT07663032RecruitingPhase 1
Pan-Salmonella vaccine study for healthy young adults
This trial tests an experimental vaccine designed to protect against multiple types of Salmonella bacteria (which cause typhoid fever and other infections). It is given to healthy adults aged 18 to 45 to check safety and immune response.
BloemfonteinAges 18–45 - NCT06839456RecruitingPhase 1/Phase 2
Stem cell addback to prevent infections after transplant
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT05077527RecruitingPhase 1
CAR-T treatment for HIV and aggressive B-cell lymphoma
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Duarte, CaliforniaAges 18 years+
Hear when a new Immunization; Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunization; infection?
- Yes. Clin2 currently lists 91 recruiting immunization; infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunization; infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunization; infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.